• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>AstraZeneca PLC ADR

AstraZeneca PLC ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. AstraZeneca Announces Phase III Results for Lesinurad in Combination with Febuxostat in Tophaceous Gout Patients at European League Against Rheumatism Annual Congress (EULAR 2015)

    AstraZeneca Announces Phase III Results for Lesinurad in Combination with Febuxostat in Tophaceous Gout Patients at European League Against Rheumatism Annual Congress (EULAR 2015)

  2. Adoption of Targeted Therapy Will Improve the Global Opioid-Induced Constipation Market Through 2019: Technavio

    Adoption of Targeted Therapy Will Improve the Global Opioid-Induced Constipation Market Through 2019: Technavio

  3. AstraZeneca Research Executive Morrison Is Leaving Company

    AstraZeneca Research Executive Morrison Is Leaving Company

  4. Juno Shares Surge on Collaboration Pact With Celgene

    Juno Shares Surge on Collaboration Pact With Celgene

  5. Research and Markets: Chronic Urticaria Or Hives - Pipeline Review, H1 2015

    Research and Markets: Chronic Urticaria Or Hives - Pipeline Review, H1 2015

  6. A Makeover At The 'Other' Merck

    A Makeover At The 'Other' Merck

  7. Immune Pharmaceuticals Initiates Phase II Clinical Trials With Bertilimumab In Ulcerative Colitis And Bullous Pemphigoid

    Immune Pharmaceuticals Initiates Phase II Clinical Trials With Bertilimumab In Ulcerative Colitis And Bullous Pemphigoid

  8. ADC Therapeutics Appoints Dr. Chris Martin as Chief Executive Officer

    ADC Therapeutics Appoints Dr. Chris Martin as Chief Executive Officer

  9. Research and Markets: Ion Channel Modulators - Global Strategic Business Report 2015

    Research and Markets: Ion Channel Modulators - Global Strategic Business Report 2015

  10. Research and Markets: Orphan Drugs - 2015 Global Strategic Business Report: Strong Market Potential for Ultra-Orphan Drugs for Amyloid Light-chain Amyloidosis

    Research and Markets: Orphan Drugs - 2015 Global Strategic Business Report: Strong Market Potential for Ultra-Orphan Drugs for Amyloid Light-chain Amyloidosis

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.